Trius Therapeutics Inc. has been another IPO with significant insider purchases. The total value of insider purchases in TSRX reached $54.4 million at a price of $5 per share. The stock has so far been a big disappointment. On September 18, 2010 it closed at $4.50 and the return in one and a half months has been -10%.
There have not been any recent insider purchases even though the stock price dipped below $4 at some point. Usually in companies with deep insider conviction we would see some insider purchases after huge declines. One possible explanation could be that they are in a blackout period and they are not allowed to trade.